Skip to main content
Nina Wagner-Johnston, MD, Oncology, Washington, DC

NinaDelaneyWagner-JohnstonMD

Oncology Washington, DC

Assistant Professor, Internal Medicine, Washington University School of Medicine

Dr. Wagner-Johnston is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Wagner-Johnston's full profile

Already have an account?

  • Office

    5255 Loughboro Road Northwest
    Washington, DC 20016
    Phone+1 202-660-6500
    Fax+1 202-660-6501

Education & Training

  • Johns Hopkins University
    Johns Hopkins UniversityFellowship, Hematology and Medical Oncology, 2005 - 2008
  • University of Chicago
    University of ChicagoResidency, Internal Medicine, 2003 - 2005
  • University of Chicago Division of the Biological Sciences The Pritzker School of Medicine
    University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 2003

Certifications & Licensure

  • MD State Medical License
    MD State Medical License 2005 - 2025
  • DC State Medical License
    DC State Medical License 2022 - 2024
  • PA State Medical License
    PA State Medical License 2024 - 2024
  • MO State Medical License
    MO State Medical License 2008 - 2016
  • IL State Medical License
    IL State Medical License 2003 - 2006

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification Allscripts Enterprise EHR, Allscripts, 2012

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • A Phase IB Study of Blinatumomab (blina) in Patients with B Cell Acute Lymphoblastic Leukemia (ALL) and B-Cell Non-Hodgkin Lymphoma (NHL) As Post-Allogeneic Blood or M...
    Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pat...
    Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
  • Allogenic Stem Cell Transplantation for Secondary CNS Lymphoma: A Retrospective Review of 21 Patients
    Nina D. Wagner-Johnston, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Join now to see all

Lectures

  • Long-Term Follow-up of Idelalisib Monotherapy in Patients with Double-Refractory Marginal Zone Lymphoma or Lymphoplasmacytic Lymphoma/ Waldenstrom's Macroglobulinemia 
    61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
  • Checkpoint Blockade Therapy May Sensitize Aggressive and Indolent Non-Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Checkpoint Blockade Therapy May Sensitize Hodgkin Lymphoma to Subsequent Therapy 
    2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
  • Join now to see all

Press Mentions

  • Treatment Options in MCL: What Are the Best Practices?
    Treatment Options in MCL: What Are the Best Practices?September 12th, 2024
  • Pain Pointers
    Pain PointersJune 1st, 2021
  • Dual Expression of MYC, BCL2 Associated with Poorer Outcomes in DLBCL
    Dual Expression of MYC, BCL2 Associated with Poorer Outcomes in DLBCLMay 26th, 2017

Professional Memberships